Focus: Moderna is a Cambridge-based mRNA therapeutics company with 5,900 employees that has rapidly scaled from a 2010 startup to a public biotech leader generating $6.8B in FY2025 revenue. The company operates across vaccines, oncology, rare diseases, and infectious disease with a platform-driven business model centered on mRNA technology.
Profile data last refreshed 11h ago · AI intelligence enriched 4d ago
Hot — 243 jobs added in 30d
Net +167 (243 new, 76 removed). Aggressive expansion phase.
Best for scientists and engineers seeking exposure to cutting-edge mRNA biology and oncology with platform upside; higher risk for those prioritizing near-term revenue stability or cash flow visibility.
Recently approved RSV vaccine in growth phase; represents platform expansion beyond COVID into seasonal vaccine markets.
Help build intelligence for Moderna
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Moderna's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Commercial anchor product that generated $19.3B in FY2024 but faces normalized demand post-pandemic; core revenue driver now normalizing.
Is Moderna, Merck's mRNA cancer vaccine win the start of a 'personalized medicine revolution'? - Fierce Biotech
Is Moderna, Merck's mRNA cancer vaccine win the start of a 'personalized medicine revolution'? Fierce Biotech
Clinical trials: New mRNA cancer vaccine plus Keytruda sharply improves melanoma survival - uchealth.org
Clinical trials: New mRNA cancer vaccine plus Keytruda sharply improves melanoma survival uchealth.org
Moderna widens mRNA cancer push with solo vaccine and in vivo CAR-T; Korea trials advance - CHOSUNBIZ - biz.chosun.com
Moderna widens mRNA cancer push with solo vaccine and in vivo CAR-T; Korea trials advance - CHOSUNBIZ biz.chosun.com
Why Moderna's Cancer Vaccine Matters To Investors - ETF Database
Why Moderna's Cancer Vaccine Matters To Investors ETF Database
The cancer vaccine made by Moderna and Merck would be a first for algorithm-fueled medicine - The Boston Globe
The cancer vaccine made by Moderna and Merck would be a first for algorithm-fueled medicine The Boston Globe
After a rough stretch, mRNA gets a boost — at least for now - STAT
After a rough stretch, mRNA gets a boost — at least for now STAT
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Phase 1/2 randomized, observer-blind clinical trial of a first-generation, mRNA-based vaccine against seasonal influenza and COVID-19 in healthy adults.
Coadministration of mRNA-1345 RSV vaccine with high-dose quadrivalent influenza vaccine in adults aged 65 and older: An observer-blinded, placebo-controlled, randomized, phase 3 trial.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo